Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
- Conference Call and Webcast Scheduled for
2:00 PM PT /5:00 PM ET
Listen-Only Webcast
The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.
Conference Call Registration
If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.
About
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T products for cancer and the potential benefits of AlloCAR T. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the
AlloCAR T™ is a trademark of
Allogene Media/Investor Contact:
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com
Senior Manager,
Jessica.Bernstein@allogene.com

Source: Allogene Therapeutics, Inc.